Macquarie Group LTD Esperion Therapeutics, Inc. Transaction History

Macquarie Group LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.02 - $3.02 $18,614 - $27,829	9,215 New	9,215 $24,000
Q4 2021 Feb 11, 2022	SELL	$4.81 - $11.92 $4,694 - $11,633	-976 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$25.12 - $36.89 $9,796 - $14,387	-390 Reduced 28.55%	976 $27,000
Q2 2020 Aug 11, 2020	BUY	$30.04 - $51.31 $41,034 - $70,089	1,366 New	1,366 $70,000
Q3 2018 Nov 15, 2018	SELL	$40.74 - $51.41 $667,932 - $842,866	-16,395 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$36.2 - $76.4 $1.28 Million - $2.7 Million	-35,364 Reduced 68.32%	16,395 $642,000
Q1 2018 May 11, 2018	BUY	$65.94 - $80.76 $2.05 Million - $2.51 Million	31,048 Added 149.91%	51,759 $3.74 Million
Q4 2017 Feb 15, 2018	SELL	$43.47 - $67.43 $113,804 - $176,531	-2,618 Reduced 11.22%	20,711 $1.36 Million
Q3 2017 Nov 08, 2017	BUY	$43.8 - $52.77 $1.02 Million - $1.23 Million	23,329	23,329 $1.17 Million

209

129M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $125M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.